Clinical Trial Applications: Filter, Search, and view applications


Clear
Extended search...

Page 2 of 87, showing 5 Applications out of 435 total, starting on record 6, ending on 10

# Protocol No Study Title Investigator(s) & Site(s)

6.

ECCT/24/02/03   MPZ-MAL-01
    A Phase 2a, Multicenter, Open-label, Dose-finding, Dose Escalation Study of Meplazumab in Adult Patients Diagnosed with   Uncomplicated Plasmodium falciparum Malaria       
Principal Investigator(s)
1. Videlis Nduba
Site(s) in Kenya
1. Kenya Medical Research Institute(KEMRI):Siaya Clinical Research Annex (Siaya county)
2. Victoria Biomedical Research Institute (VIBRI) (Kisumu county)
3. AHERO CLINICAL TRIALS UNIT (Kisumu county)
 
View

7.

ECCT/23/11/05   Alma Study
    Feasibility clinical study of the Alma system in treating Primary Postpartum Hemorrhage - Alma Study    
Principal Investigator(s)
1. Omondi Ogutu
Site(s) in Kenya
Kenyatta National Hospital
 
View

8.

ECCT/23/11/06   MPZ-MAL-01
    A Phase 2a, Multicenter, Open-label, Dose-finding, Dose Escalation Study of Meplazumab in Adult Patients Diagnosed with Uncomplicated Plasmodium falciparum Malaria   
Principal Investigator(s)
1. Bernhards Ogutu
Site(s) in Kenya
1. AHERO CLINICAL TRIALS UNIT (Kisumu county)
2. Victoria Biomedical Research Institute (VIBRI) (Kisumu county)
3. Kenya Medical Research Institute(KEMRI):Siaya Clinical Research Annex (Siaya county)
 
View

9.

ECCT/23/11/01   MPZ-MAL-01
    A Phase 2a, Multicenter, Open-label, Dose-finding, Dose Escalation Study of Meplazumab in Adult Patients Diagnosed with Uncomplicated Plasmodium falciparum Malaria   
Principal Investigator(s)
1. Lucas Otieno Tina
Site(s) in Kenya
1. Victoria Biomedical Research Institute (VIBRI) (Kisumu county)
2. AHERO CLINICAL TRIALS UNIT (Kisumu county)
3. Kenya Medical Research Institute(KEMRI):Siaya Clinical Research Annex (Siaya county)
 
View

10.

ECCT/23/11/04   AUB Study
    A phase 1, single-center, double-blind, randomized, placebo-controlled trial to assess the safety, tolerability and initial efficacy of AHC01 delivered via transcervical catheter in adult females (25-55 years), experiencing abnormal uterine bleeding and scheduled for a hysterectomy.   
Principal Investigator(s)
1. Dr Alice Kaaria
Site(s) in Kenya
Kenyatta National Hospital (KNH)
 
View